Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.

Mersiha Hadziahmetovic, Billy W. Loo, Robert D. Timmerman, Nina A. Mayr, Jian Z. Wang, Zhibin Huang, John C. Grecula, Simon S. Lo

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), has emerged as one of the standard treatment options for stage I non-small cell lung cancer (NSCLC), mainly in medically inoperable patients. Its use has also been explored in operable patients. A large body of experience, either from retrospective studies or clinical trials, has been accumulated over the years and more is known about the radiobiology, cancer biology, technical aspects, clinical outcomes, and toxicities of SBRT. This article provides updates of these aspects of SBRT for stage I NSCLC.

Original languageEnglish (US)
Pages (from-to)411-417
Number of pages7
JournalDiscovery medicine
Volume9
Issue number48
StatePublished - May 2010

Fingerprint

Radiobiology
Non-Small Cell Lung Carcinoma
Radiotherapy
Retrospective Studies
Clinical Trials
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes. / Hadziahmetovic, Mersiha; Loo, Billy W.; Timmerman, Robert D.; Mayr, Nina A.; Wang, Jian Z.; Huang, Zhibin; Grecula, John C.; Lo, Simon S.

In: Discovery medicine, Vol. 9, No. 48, 05.2010, p. 411-417.

Research output: Contribution to journalArticle

Hadziahmetovic, Mersiha ; Loo, Billy W. ; Timmerman, Robert D. ; Mayr, Nina A. ; Wang, Jian Z. ; Huang, Zhibin ; Grecula, John C. ; Lo, Simon S. / Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes. In: Discovery medicine. 2010 ; Vol. 9, No. 48. pp. 411-417.
@article{ad136c0801684f7584411672875d60bd,
title = "Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.",
abstract = "Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), has emerged as one of the standard treatment options for stage I non-small cell lung cancer (NSCLC), mainly in medically inoperable patients. Its use has also been explored in operable patients. A large body of experience, either from retrospective studies or clinical trials, has been accumulated over the years and more is known about the radiobiology, cancer biology, technical aspects, clinical outcomes, and toxicities of SBRT. This article provides updates of these aspects of SBRT for stage I NSCLC.",
author = "Mersiha Hadziahmetovic and Loo, {Billy W.} and Timmerman, {Robert D.} and Mayr, {Nina A.} and Wang, {Jian Z.} and Zhibin Huang and Grecula, {John C.} and Lo, {Simon S.}",
year = "2010",
month = "5",
language = "English (US)",
volume = "9",
pages = "411--417",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "48",

}

TY - JOUR

T1 - Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.

AU - Hadziahmetovic, Mersiha

AU - Loo, Billy W.

AU - Timmerman, Robert D.

AU - Mayr, Nina A.

AU - Wang, Jian Z.

AU - Huang, Zhibin

AU - Grecula, John C.

AU - Lo, Simon S.

PY - 2010/5

Y1 - 2010/5

N2 - Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), has emerged as one of the standard treatment options for stage I non-small cell lung cancer (NSCLC), mainly in medically inoperable patients. Its use has also been explored in operable patients. A large body of experience, either from retrospective studies or clinical trials, has been accumulated over the years and more is known about the radiobiology, cancer biology, technical aspects, clinical outcomes, and toxicities of SBRT. This article provides updates of these aspects of SBRT for stage I NSCLC.

AB - Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), has emerged as one of the standard treatment options for stage I non-small cell lung cancer (NSCLC), mainly in medically inoperable patients. Its use has also been explored in operable patients. A large body of experience, either from retrospective studies or clinical trials, has been accumulated over the years and more is known about the radiobiology, cancer biology, technical aspects, clinical outcomes, and toxicities of SBRT. This article provides updates of these aspects of SBRT for stage I NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=77956637854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956637854&partnerID=8YFLogxK

M3 - Article

C2 - 20515609

AN - SCOPUS:77956637854

VL - 9

SP - 411

EP - 417

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 48

ER -